Cabergoline Effect on Blood Sugar in Type 2 Diabetics

Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01459601

Enrollment

Registered

2011-10-25

Start date

2012-01-31

Completion date

2012-02-29

Last updated

2011-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Type 2

Keywords

diabetes mellitus, FBS, HbA1C, Cabergoline

Brief summary

Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.

Interventions

DRUGCabergoline

0,5mg per week

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Type 2 diabetes * HbA1C\>7

Exclusion criteria

* HbA1C\>10 * Psychiatric disorders

Design outcomes

Primary

Measure	Time frame
FBS (fasting blood sugar)	30days

Secondary

Measure	Time frame
HbA1C	30days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026